Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000950170-25-064711
Filing Date
2025-05-06
Accepted
2025-05-06 17:55:07
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 7663
2 EX-99.5 ck0001669811-ex99_5.pdf EX-99.5 87713
  Complete submission text file 0000950170-25-064711.txt   130668
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Subject) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-79996 | Film No.: 25918630
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 223 S. WEST STREET, SUITE 900 RALEIGH NC 27603
Business Address 223 S. WEST STREET, SUITE 900 RALEIGH NC 27603 800-683-5555
Foundation Fighting Blindness Retinal Degeneration Fund (Filed by) CIK: 0002042266 (see all company filings)

EIN.: 450524687 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A